메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 31, Issue 22, 2013, Pages 2836-2837
Reply to K.S. Wilson et al
Author keywords

[No Author keywords available]
Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; LACTATE DEHYDROGENASE; TICILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;
EID: 84884733001     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.2120     Document Type: Letter
Times cited : (8)
References (8)
  • 1
    • 84884744256 scopus 로고    scopus 로고
    • Is tremelimumab beneficial in advanced melanoma?
    • Wilson KS, Kotb R: Is tremelimumab beneficial in advanced melanoma? J Clin Oncol 31:2835, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 2835
    • Wilson, K.S.1    Kotb, R.2
  • 2
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3
  • 3
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363:711-723, 2010
    • (2010) New Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 4
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 364:2517-2526, 2011
    • (2011) New Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 5
    • 61449090474 scopus 로고    scopus 로고
    • Phase I/II trial of tremelimumab in patients with metastatic melanoma
    • Camacho LH, Antonia S, Sosman J, et al: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075-1081, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 1075-1081
    • Camacho, L.H.1    Antonia, S.2    Sosman, J.3
  • 6
    • 78449250123 scopus 로고    scopus 로고
    • Clinical development of the anti-CTLA-4 antibody tremelimumab
    • Ribas A: Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 37:450-454, 2010
    • (2010) Semin Oncol , vol.37 , pp. 450-454
    • Ribas, A.1
  • 7
    • 76049092889 scopus 로고    scopus 로고
    • Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
    • Kirkwood JM, Lorigan P, Hersey P, et al: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16:1042-1048, 2010
    • (2010) Clin Cancer Res , vol.16 , pp. 1042-1048
    • Kirkwood, J.M.1    Lorigan, P.2    Hersey, P.3
  • 8
    • 77955256254 scopus 로고    scopus 로고
    • Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study
    • O'Day SJ, Maio M, Chiarion-Sileni V, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21:1712-1717, 2010
    • (2010) Ann Oncol , vol.21 , pp. 1712-1717
    • O'Day, S.J.1    Maio, M.2    Chiarion-Sileni, V.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.